Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery

Molecular Pharmaceutics

Volumn 9, Issue 10, 2012, Pages 2933-2941

  Sakuma, Shinji ^a   Suita, Masaya ^a   Inoue, Saki ^a   Marui, Yoko ^a   Nishida, Kazuhiro ^a   Masaoka, Yoshie ^a   Kataoka, Makoto ^a   Yamashita, Shinji ^a   Nakajima, Noriko ^b   Shinkai, Norihiro ^b   Yamauchi, Hitoshi ^b   Hiwatari, Ken Ichiro ^c   Tachikawa, Hiroyuki ^c   Kimura, Ryoji ^c   Uto, Tomofumi ^d   Baba, Masanori ^d  

^a SETSUNAN UNIVERSITY   (Japan)

^b Nipro Patch Co Ltd   (Japan)

^c ADEKA CORPORATION   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CELL PENETRATING PEPTIDE; CHOLERA TOXIN B SUBUNIT; DRUG CARRIER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; OVALBUMIN; PHOSPHATE BUFFERED SALINE; POLY(N VINYLACETAMIDE CO ACRYLIC ACID); POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHEMICAL STRUCTURE; CIRCULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; PRIORITY JOURNAL; ZETA POTENTIAL;

EID: 84870198280     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300329r     Document Type: Article

References (27)

1. Yuki, Y.; Kiyono, H. New generation of mucosal adjuvants for the induction of protective immunity Rev. Med. Virol. 2003, 13, 293-310
2. Okamoto, S.; Matsuura, M.; Akagi, T.; Akashi, M.; Tanimoto, T.; Ishikawa, T.; Takahashi, M.; Yamanishi, K.; Mori, Y. Poly(γ-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice Vaccine 2009, 27, 5896-5905
3. Mizuno, D.; Kurihara, M. I.; Ichinomiya, T.; Kubo, I.; Kido, H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen J. Immunol. 2006, 176, 1122-1130
4. Greenbaum, E.; Furst, A.; Kiderman, A.; Stewart, B.; Levy, R.; Schlesinger, M.; Morag, A.; Zakay-Rones, Z. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine J. Med. Virol. 2001, 65, 178-184
5. Tamura, S. I.; Asanuma, H.; Ito, Y.; Hirabayashi, Y.; Suzuki, Y.; Nagamine, T.; Aizawa, C.; Kurata, T.; Oya, A. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine Eur. J. Immunol. 1992, 22, 477-481
6. Takada, A.; Matsushita, S.; Ninomiya, A.; Kawaoka, Y.; Kida, H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtype immunity against influenza A virus infection in mice Vaccine 2003, 21, 3212-3218
7. Liew, F. Y.; Russell, S. M.; Appleyard, G.; Brand, C. M.; Beale, J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity Eur. J. Immunol. 1984, 14, 350-356
8. Glück, R.; Mischler, R.; Durrer, P.; Fürer, E.; Lang, A. B.; Herzog, C.; Cryz, S. J., Jr. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant J. Infect. Dis. 2000, 181, 1129-1132
9. Tamura, S.; Yamanaka, A.; Shimohara, M.; Tomita, T.; Komase, K.; Tsuda, Y.; Suzuki, Y.; Nagamine, T.; Kawahara, K.; Danbara, H. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine Vaccine 1994, 12, 419-426
10. Hashigucci, K.; Ogawa, H.; Ishidate, T.; Yamashita, R.; Kamiya, H.; Watanabe, K.; Hattori, N.; Sato, T.; Suzuki, Y.; Nagamine, T.; Aizawa, C.; Tamura, S.; Kurata, T.; Oya, A. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin Vaccine 1996, 14, 113-119
11. Mutsch, M.; Zhou, W.; Rhodes, P.; Bopp, M.; Chen, R. T.; Linder, T.; Spyr, C.; Steffen, R. Use of the inactivated internasal influenza vaccine and the risk of Bell's palsy in Switzerland N. Engl. J. Med. 2004, 350, 896-903
12. Durrer, P.; Glück, U.; Spyr, C.; Lang, A. B.; Zurbriggen, R.; Herzog, C.; Glück, R. Mucosal antibody response induced with a nasal virosome-based influenza vaccine Vaccine 2003, 21, 4328-4334
13. de Bernardi di Valserra, M.; Zanasi, A.; Ragusa, S.; Glück, R.; Herzog, C. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults Clin. Ther. 2002, 24, 100-111
14. Ichinohe, T.; Watanabe, I.; Ito, S.; Fujii, H.; Moriyama, M.; Tamura, S.; Takahashi, H.; Sawa, H.; Chiba, J.; Kurata, T.; Sata, T.; Hasegawa, H. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection J. Virol. 2005, 79, 2910-2919
15. Uto, T.; Akagi, T.; Hamasaki, T.; Akashi, M.; Baba, M. Modulation of innate and adaptive immunity by biodegradable nanoparticles Immunol. Lett. 2009, 125, 46-52
16. Uto, T.; Wang, X.; Akagi, T.; Zenkyu, R.; Akashi, M.; Baba, M. Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles Biochem. Biophys. Res. Commun. 2009, 379, 600-604
17. Uto, T.; Wang, X.; Sato, K.; Haraguchi, M.; Akagi, T.; Akashi, M.; Baba, M. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity J. Immunol. 2007, 178, 2979-2986
18. Sakuma, S.; Suita, M.; Masaoka, Y.; Kataoka, M.; Nakajima, N.; Shinkai, N.; Yamauchi, H.; Hiwatari, K.; Tachikawa, H.; Kimura, R.; Yamashita, S. Oligoarginine-linked polymers as a new class of penetration enhancers J. Controlled Release 2010, 148, 187-196
19. Sakuma, S.; Suita, M.; Yamamoto, T.; Masaoka, Y.; Kataoka, M.; Yamashita, S.; Nakajima, N.; Shinkai, N.; Yamauchi, H.; Hiwatari, K.; Hashizume, A.; Tachikawa, H.; Kimura, R.; Ishimaru, Y.; Kasai, A.; Maeda, S. Performance of cell-penetrating peptide-linked polymers physically mixed with poorly membrane-permeable molecules on cell membranes Eur. J. Pharm. Biopharm. 2012, 81, 64-73
20. Futaki, S. Membrane-permeable arginine-rich peptides and the translocation mechanisms Adv. Drug Delivery Rev. 2005, 57, 547-558
21. Nakase, I.; Takeuchi, T.; Tanaka, G.; Futaki, S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides Adv. Drug Delivery Rev. 2008, 60, 598-607
22. Jones, A. T. Macropinocytosis: Searching for an endocytic identity and a role in the uptake of cell penetrating peptides J. Cell. Mol. Med. 2007, 11, 670-684
23. Sakuma, S.; Hayashi, M.; Akashi, M. Design of nanoparticles composed of graft copolymers for oral peptide delivery Adv. Drug Delivery Rev. 2001, 47, 21-37
24. Nichol, K. L. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines Vaccine 2003, 21, 1769-1775
25. Belshe, R. B. Current status of live attenuated influenza virus vaccine in the US Virus Res. 2004, 103, 177-185
26. Petrovsky, N.; Aguilar, J. C. Vaccine adjuvants: Current state and future trends Immunol. Cell Biol. 2004, 82, 488-496
27. Sakuma, S.; Sudo, R.; Suzuki, N.; Kikuchi, H.; Akashi, M.; Ishida, Y.; Hayashi, M. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine J. Controlled Release 2002, 81, 281-290